Search for content and authors
 

Synthesis of novel 2-benzylthio-4-chloro-N-(5-substituted 1,2,4-triazin-3-yl)benzenesulfonamide derivatives with potential antitumor activity

Jarosław J. Sławiński 1Beata Żołnowska 1Anna Kawiak 2Aleksandra Grzonek 1Joanna Jasińska 1

1. Medical University of Gdańsk, Department of Organic Chemistry, Gen. J. Hallera Street 107, Gdańsk 80-416, Poland
2. Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Kladki 24, Gdańsk 80-822, Poland

Abstract

Recently, we reported on the significant anticancer activity of a series of 2-mercapto-N-(1,2,4-triazin-3-yl)benzenesulfonamides bearing phenyl or substituted phenyl attached to the 1,2,4-triazine moiety simultaneously at positions 5 and 6 [1]. In the present study, in search for even more potent 2-mercaptobenzenesulfonamides we elaborated the synthesis and anticancer evaluations in vitro of novel N-(5-substituted 1,2,4-triazin-3-yl)benzenesulfonamide derivatives as depicted in scheme below.
The synthesis of the desired 2-benzylthio-4-chloro-N-(5-aryl-1,2,4-triazin-3-yl)benzenesulfonamide derivatives were  achieved by reacting of the corresponding 3-amino-2-(benzenesulfonyl)guanidines [2,3] with suitable phenylglyoxal hydrate in refluxing glacial acetic acid for at least 30 hours. The structure of the obtained compounds was confirmed by elemental analyses, and IR, 1H and 13C NMR spectroscopy.

Anticancer in vitro screening was performed at the Department of Biotechnology, Intercollegiate Faculty of Biotechnology UG-MUG with using three cell lines of breast (MCF-7), colon (HCT-116) and cervix cancer (HeLa), and at the NCI (Bethesda MD, USA) using 60 cell lines derived from 9 types of human tumors. This tests revealed moderate or reasonable anticancer activity of tested compounds.
The distinctive compound, i.e. 2-benzylthio-4-chloro-N-[5-(3-methoxyphenyl)-1,2,4-triazin-3-yl]-5-methylbenzenesulfonamide showed remarkable activity against 23 of human tumor cell lines representing leukemia, lung, colon, CNS, melanoma, ovarian, renal and breast at low micromolar GI50 level in the range of 13.8 – 19.9 μM.

References:
1. Sławiński J., Gdaniec M., Eur. J. Med. Chem., 40, 377 (2005).
2. Sławiński J., Polish J. Chem., 75, 1309 (2001).
3. Sławiński J., Bednarski P., Grünert R., Reszka P., Polish J. Chem., 77, 53 (2003).

This project was financed by National Science Centre (NCN) based on the decision number DEC-2013/09/B/NZ7/00048.

 

Legal notice
  • Legal notice:
 

Related papers

Presentation: Poster at IX Multidyscyplinarna Konferencja Nauki o Leku, by Jarosław J. Sławiński
See On-line Journal of IX Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2014-03-10 11:15
Revised:   2014-05-02 19:00